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Original Article
Neurovascular coupling and cerebral
autoregulation in atrial fibrillation
Rehan T Junejo1,2 , Igor D Braz3, Samuel JE Lucas1,4,
Johannes J van Lieshout5,6,7, Aaron A Phillips8,
Gregory YH Lip2 and James P Fisher1,9
Abstract
The risk of cognitive decline and stroke is increased by atrial fibrillation (AF). We sought to determine whether
neurovascular coupling and cerebral autoregulation are blunted in people with AF in comparison with age-matched,
patients with hypertension and healthy controls. Neurovascular coupling was assessed using five cycles of visual stimu-
lation for 30 s followed by 30 s with both eyes-closed. Cerebral autoregulation was examined using a sit–stand test, and a
repeated squat-to-stand (0.1 Hz) manoeuvre with transfer function analysis of mean arterial pressure (MAP; input) and
middle cerebral artery mean blood flow velocity (MCA Vm; output) relationships at 0.1 Hz. Visual stimulation increased
posterior cerebral artery conductance, but the magnitude of the response was blunted in patients with AF (18 [8] %;
mean [SD]) and hypertension (17 [8] %), in comparison with healthy controls (26 [9] %) (P< 0.05). In contrast, trans-
mission of MAP to MCA Vm was greater in AF patients compared to hypertension and healthy controls, indicating
diminished cerebral autoregulation. We have shown for the first time that AF patients have impaired neurovascular
coupling responses to visual stimulation and diminished cerebral autoregulation. Such deficits in cerebrovascular regu-
lation may contribute to the increased risk of cerebral dysfunction in people with AF.
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Introduction
Atrial fibrillation (AF) is associated with substantial
risk of mortality and morbidity from stroke and
thromboembolism,1–3 while ischemic strokes caused
by AF are often severe and lead to low quality of life
and high mortality.4 Even in the absence of previous
stroke, patients with AF are at heightened risk of cog-
nitive decline, dementia and depression.5–7 The precise
mechanisms by which AF may precipitate such cogni-
tive dysfunction, and causes such severe cerebrovascu-
lar events, have not been fully elucidated but may
include impairments in cerebrovascular regulation.
The brain has a high metabolic demand and possesses
regulatory mechanisms to ensure a close matching of
local blood flow to neuronal activation and metabolism
(neurovascular coupling) and an adequate cerebral
oxygen delivery over a wide range of perfusion pressures
to prevent over/under perfusion and consequent risk of
haemorrhage or ischemia (cerebral autoregulation).8
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Impaired neurovascular coupling and cerebral autoregu-
lation have been identified in a number of pathologies,
including stroke and neurovascular diseases9,10; how-
ever, neither neurovascular coupling nor cerebral auto-
regulation have been examined in AF. Poor cerebral
blood flow in AF may lead to vasodilatation of cerebral
arterioles thus reducing cerebral vasodilatory reserve.11
Indeed, a 13% reduction in hemispheric cerebral blood
flow has been documented in individuals with AF aged
between 51 and 65 years, in the absence of signs of heart
failure or cerebral vascular disease.12 Moreover, systemic
endothelial dysfunction has also been reported in AF
and may impair cerebrovascular regulation. Plasma
von Willebrand factor, a biomarker of endothelial
damage/dysfunction, is raised in AF and has been
related to adverse outcomes.13 In addition, stable
patients with chronic AF have an impaired conduit (bra-
chial) artery flow-mediated dilatation response in com-
parison to sinus rhythm controls,14 indicative of
attenuated endothelial nitric oxide (NO) bioavailabil-
ity.15,16 This is important since endothelium-derived
NO is an important local regulator of cerebral blood
flow17 and some evidence indicates that it is involved
in cerebral autoregulation18,19 and neurovascular cou-
pling,20,21 although this is controversial22,23 and remains
an active area of exploration.17
We have identified a blunted cerebrovascular carbon
dioxide reactivity as an important control mechanism
of cerebral blood flow in AF patients24 and herein
sought to extend those observations by determining
whether neurovascular coupling and cerebral autoregu-
lation are impaired in AF. These key cerebrovascular
regulatory processes were assessed in patients with AF,
hypertension and healthy volunteers. Patients with
hypertension were also recruited to serve as a ‘disease
control’ group with the aim of controlling for the effect
of medications and comorbidities.24,25 We hypothesized
that neurovascular coupling and cerebral autoregula-
tion would be poorer in patients with AF when com-
pared to age-matched healthy controls and patients
with hypertension.
Material and methods
Ethical approval
This study was approved by the National Research
Ethics Service Committee West Midlands (13/WM/
0210 and 15/WM/0447) and adhered to the principles
of the Declaration of Helsinki (2008). Prospective par-
ticipants were provided with an information sheet and
all procedures were verbally explained in detail. All vol-
unteers provided written informed consent after having
the opportunity to ask questions and receive appropri-
ate clarification.
Participants
Eighty-three people were recruited to participate in this
cross sectional, case control study, across three groups:
AF patients (n¼ 30), primary hypertensive patients in
sinus rhythm (n¼ 29), and healthy control participants
(n¼ 24). AF and hypertension patients were recruited
from dedicated clinics at City Hospital, Birmingham,
United Kingdom, while healthy controls were recruited
from the surrounding communities by recruitment
advertisements and word of mouth. In addition, GP
practices within the National Institute of Health
Research Clinical Research Network were also
employed to recruit participants to all groups.
Individuals with a fast ventricular rate (> 90 b/min),
left ventricular dysfunction, valvular heart disease, pre-
vious myocardial infarction, angina, ischemic and
haemorrhagic stroke / transient ischemic attack, malig-
nancy, uncontrolled thyroid disorders, insulin-
dependent diabetes, secondary hypertension and
respiratory, hepatic, renal, connective tissue, inflamma-
tory or neurological diseases were excluded from par-
ticipation. Also excluded were those using oral nitrates,
hormone replacement therapy, smokers and those with
a weekly alcohol consumption of> 28 units. Participant
characteristics and prescribed medication use are pro-
vided in Table 1.
AF patients were previously diagnosed with parox-
ysmal (i.e. episodes are transient and spontaneously
resolve) or persistent AF (i.e. each untreated epi-
sode lasts longer than seven days), while patients
with hypertension were also previously clinically diag-
nosed (i.e. consistent non-clinical ambulatory blood
pressure readings of systolic >140mmHg and/or
diastolic> 90mmHg). Four healthy participants were
found to have raised blood pressure and were referred
to a GP but upon follow-up all were confirmed as being
normotensive.
Experimental measures
Baseline brachial arterial pressure was determined non-
invasively using an automated oscillometer (M2,
Omron, Kyoto, Japan). Continuous beat-by-beat
blood pressure was obtained using finger photoplethys-
mography (Finometer MIDI, Finapres Medical
Systems, Amsterdam, The Netherlands) and heart
rate (HR) was monitored by a lead II ECG (BioAmp,
ADInstruments, Dunedin, New Zealand). Middle cere-
bral artery mean blood velocity (MCA Vm) was con-
tinuously recorded in all participants, while posterior
cerebral artery mean blood velocity (PCA Vm) was
obtained in a sub-set of participants, using a 2MHz
transcranial Doppler probe (Doppler BoxX, DWL,
Sipplingen, Germany) fixed at the temporal window
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with an adjustable headband and ultrasound gel.
MCA insonation was attempted on both sides
with recordings made from optimal side; the contralat-
eral PCA was then insonated and again data only
from optimally insonated vessels were recorded.
Vessels were confirmed in accordance with published
guidelines.26 Minute ventilation was measured
using an oronasal mask connected to a heated pneumo-
tach (Hans Rudolph, Kansas City, KS, USA).
Continuous breath-by-breath partial pressure of
end-tidal carbon dioxide (PETCO2) was obtained
by a capnograph connected to the mask by a sample
line (RespSense, Nonin Medical, Plymouth,
MN, USA).
Study protocol
Baseline. Participants refrained from taking medications
(excluding anticoagulants) on the morning before the
study. Height and weight were measured. After instru-
mentation, a 10-min baseline was acquired while par-
ticipants lay supine breathing room air. At least three
brachial artery blood pressure readings were obtained
during this period.
Table 1. Participant characteristics.
HC AF HT P value
n 24 30 29
Age (yr) 68 [66, 70] 69 [63, 72] 68 [65, 72] 0.95
Sex (n women) 11 9 14 –
Waist/hip (ratio) 0.84 [0.79, 0.90] 0.86 [0.83, 0.93] 0.88 [0.85, 0.92] 0.38
BMI (kg/m2) 24.3 [22.9, 25.6] 27.0 [24.4, 29.8]* 26.0 [25.2, 28.5]* <0.01
Hypertension (n) – 18 29 –
Type II diabetes (n) – 1 4 –
HR (bpm) 60 [56, 65] 62 [58, 74] 62 [57, 68] 0.28
SBP (mmHg) 141 (21) 135 (24)y 153 (17) 0.01
DBP (mmHg) 81 (08) 82 (12) 85 (11) 0.42
MAP (mmHg) 101 (11) 100 (13) 108 (13) 0.047
MCA Vm (cm/s) 62 (14) 51 (13)* 54 (11) 0.01
PCA Vm (cm/s) 34 (13) 33 (8) 34 (7) 0.42
PETCO2 (mmHg) 40.2 (4.6) 38.1 (5.2)
y 42.2 (4.3) 0.01
CHADS2 Score – 1 [0, 1] – –
CHA2DS2-VASc Score – 2 [1, 2] – –
Medications (n)
b-blockers – 12 2 –
ACEi – 7 11 –
ARB – 2 7 –
Caþþ channel blockers – 7 13 –
Diuretics – 3 8 –
OACs – 22 – –
Low-dose salicylates – 3 3 –
Digoxin – 3 – –
Statins 5 15 12 –
Biguanides – 1 4 –
DPP-4 inhibitors – – 1 –
Sulfonylureas – – 2 –
Thiazolidinediones – – 1 –
Note: Values are displayed as mean (SD) when normally distributed or median [interquartile range] when non-normally distributed. HC: healthy
control; AF: atrial fibrillation; HT: hypertension; BMI: body mass index; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure;
MAP: mean arterial pressure; MCA Vm: mean middle cerebral artery blood flow velocity; PCA Vm: mean posterior cerebral artery blood flow velocity;
PETCO2: end-tidal partial pressure of CO2; ACEi: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; DPP-4: Dipeptidyl
peptidase-4; OACs: oral anticoagulants.
*P< 0.05 vs. HC; yP< 0.05 vs. HT. PCA signals were obtained at baseline in a subgroup of HC (n¼ 12), AF (n¼ 13) and HT (n¼ 16) participants.
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Neurovascular coupling. Following a 2-min baseline
period with both eyes closed, five cycles of 30 s with
eyes open (visual stimulation – silent reading) followed
by 30 s eyes closed were performed. Reading material
consisted of general tourist information relating to
Birmingham, UK. The neurovascular coupling proto-
col was undertaken in accordance with published
guidelines.21
Sit–stand. Cerebral autoregulation was assessed by per-
forming a single sit-to-stand. Participants sat comfort-
ably with the legs uncrossed on a chair for 2min
followed by single movement to a standing position,
which was maintained for a further 2min.
Squat-to-stand. Following 2-min of standing, partici-
pants performed a repeated squat-to-stand manoeuvre
for 5-min (0.1Hz). Squats consisted of bending the
knees at 90 for 5 s followed by standing straight for
a further 5 s. This manoeuvre produces large amplitude
oscillations in blood pressure and cerebral blood flow
velocity, thus increasing the coherence between these
signals and optimizing the transfer function analysis
method and its reproducibility.27,28
Data analysis
Study design restricted blinding during data collection.
However, researchers were blinded during data and
statistical analysis. Body mass index (BMI) was
expressed as the ratio between participant’s weight
and the square of their height. Cardiorespiratory and
transcranial Doppler signals were digitized at 1 kHz
(Powerlab, ADInstruments) and recorded using multi-
channel data acquisition software (LabChart 7,
ADInstruments). Mean blood pressure of each cardiac
cycle was calculated as the mean arterial pressure
(MAP), while an index of the cerebrovascular conduct-
ance (CVCi) was calculated using the following formula
MCACVCi or PCACVCi ¼
MCAVm or PCAVm
MAP
Baseline values for cardiorespiratory and cerebro-
vascular data were averaged over 10min. For neurovas-
cular coupling analysis, beat-to-beat (cardiovascular
and cerebrovascular) and breath-by-breath (respira-
tory) data underwent cubic spline interpolation at
5Hz using a custom built Matlab code (MathWorks,
United States). The average values of MCA Vm,
MCACVCi, PCA Vm, PCACVCi, MAP and PETCO2
were calculated for the eyes open and eyes closed
phases. Additionally, peak responses to eyes open
were computed and expressed as percentage change
from eyes closed. The magnitude of the neurovascular
coupling response was principally taken as the peak
percentage change in PCACVCi. A secondary analysis
was undertaken in an attempt to better understand
the ‘‘task-specific selectivity’’ of the response, in which
the ‘‘non-selective’’ cerebrovascular responses to the
neurovascular coupling test were excluded by calculat-
ing the difference between the PCACVCi and MCACVCi
responses.
Cerebral autoregulation was determined from
cardiovascular and cerebrovascular responses to the
sit–stand manoeuvre, along with the transfer function
analysis of cardiovascular (MAP) and cerebrovascular
(MCA Vm) signals for the supine baseline (5min) and
the repeated squat-to-stand manoeuvre (5min). For
sit–stand data, baseline values of MCA Vm,
MCACVCi, MAP and PETCO2 were calculated as the
average of 20 s data before stand (i.e. while seated).
The magnitude of the change (delta; D) to nadir was
calculated along with the time to nadir. For the
repeated squat-to-stand, extracted data underwent
cubic polynomial interpolation and resampling at
10Hz for transfer function analysis using the fast
Fourier transform in accordance with the recommen-
dations of the International Cerebral Autoregulation
Research Network (CARNet, http://www.car-net.org/
content/resources).29 The relationship between input
(MAP) and output (MCA Vm) was quantified with
respects to power, absolute gain (cm/s/mmHg), normal-
ised gain (%/mmHg), phase and coherence, averaged at
0.1Hz (i.e. coincident with frequency of repeated squat
to stand).27 In addition, averages were computed over
the very low frequency (0.02–0.07Hz), low frequency
(0.07–0.2Hz), and high frequency (0.2–0.5Hz)
ranges.30
Statistical analyses
Participant numbers included for each analysis are
shown in the figure and table legends. Normality was
assessed by the Shapiro–Wilk test. Normally distribu-
ted data were analyzed using one-way analysis of vari-
ance (ANOVA) or Students t-test, while non-normally
distributed data were analyzed using Kruskal–Wallis H
test or Mann–Whitney Rank Sum test. Multiple pair-
wise comparisons were performed using Students t-test
with Bonferroni correction if a significant difference
was found by the ANOVA. When a significant differ-
ence between the groups was found by the Kruskal–
Wallis H test, post hoc analysis was performed with
Dunn’s method. Statistical analysis was performed
using Sigmaplot 13.0 (Systat Software Inc., London,
UK). Significance was set at P< 0.05. Normally distrib-
uted data are presented as mean (SD), while non-
normally distributed data are presented as median
[interquartile range]. Assuming a 6% SD for NVC as
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Nowak-Fluck et al.,31 the minimal detectable difference
between the groups would be 7% with a sample size of
12 patients in each group, at 80% power and 5% alpha.
Assuming a 0.35%/mmHg SD for normalized gain at
0.1Hz during the repeated squat-to-stand manoeuvre
as Smirl et al.,32 the minimal detectable difference
between the groups would be 0.28%/mmHg with a
sample size of 25 patients in each group, at 80%
power and 5% alpha.
Results
Baseline
Groups were closely matched for age and waist/hip
ratio, while BMI was higher in AF and hypertension
patients (Table 1). During the supine baseline, HR and
DBP were not different between groups, while SBP and
MAP were lowest in AF and highest in hypertension.
Supine MCA Vm and PETCO2 were lower in AF, while
PCA Vm was not different between groups.
Neurovascular coupling
Visual stimulation evoked an increase in PCACVCi in all
groups (Figure 1 and Table 2), but the magnitude of the
hyperaemic response was blunted in patients with AF
and hypertension, in comparison with healthy controls
(P< 0.05). AF patients exhibited the greatest increase
in MCACVCi (P< 0.05 vs. healthy controls and patients
with hypertension) and when this ‘‘non-selective’’ effect
of the neurovascular coupling test was subtracted, a
significantly diminished peak PCACVCi response was
observed in AF patients compared to both other
groups. When the peak MCA Vm was similarly
accounted for, the peak PCA Vm was also observed
to be diminished in AF patients (P< 0.05 vs. healthy
controls and patients with hypertension). The neuro-
vascular coupling test slightly elevated PETCO2, but
to a similar extent in each group. MAP was also slightly
elevated in the AF and hypertension patient groups
(P< 0.01 vs. healthy controls).
Cerebral autoregulation
Cardiovascular and cerebrovascular responses to the
sit-stand manoeuvre are provided in Table 3. No dif-
ferences were noted between the groups in terms of the
magnitude of the fall in MAP, MCA Vm or MCACVCi.
Similarly, no between group differences were noted for
the time taken to reach a nadir. Figure 2 and
Supplementary Table 1 provide transfer function ana-
lysis derived coherence, phase and gain in the very low,
low and high frequency ranges, along with 0.1Hz, both
at baseline and during a repeated squat-stand man-
oeuvre. Normalised gain was elevated in patients with
AF compared to patients with hypertension during the
repeated squat-stand manoeuvre at 0.1Hz, compared
to normotensive controls in sinus rhythm (P< 0.05).
Coherence and absolute gain were not different between
the groups during the repeated squat-stand manoeuvre
at 0.1Hz; however, phase was lower in patients with
hypertension when compared to normotensive controls
in sinus rhythm (P< 0.05). As anticipated, the
Figure 1. Neurovascular coupling response in the posterior (PCA; a) in healthy controls (HC; blue), patients with atrial fibrillation
(AF; red) and hypertension (HT; green). Lines represent the group mean responses. The black bar indicates where participants had
their eyes open. Panel b shows the individual peak PCACVCi responses (%) with mean (SD) for each group. *P< 0.05 vs HC.
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Table 2. Neurovascular coupling (NVC) responses in healthy controls (HC), patients with atrial fibrillation (AF) and hypertension
(HT).
HC AF HT P value
n 12 12 13
Baseline
PCA Vm (cm/s) 36 (8) 31 (7) 33 (8) 0.36
MCA Vm (cm/s) 60 (15) 49 (12) 55 (12) 0.13
MAP (mmHg) 99 (10) 106 (13) 112 (14) 0.06
MCACVCi (cm/s/mmHg) 0.61 (0.17) 0.47 (0.13) 0.50 (0.12)* <0.05
PCACVCi (cm/s/mmHg) 0.36 (0.09) 0.30 (0.07) 0.30 (0.07) 0.06
PETCO2 (mmHg) 41 [39–43] 39 [36–40] 43 [40–45] 0.07
Peak NVC response
D PCA Vm (%) 24 (10) 19 (7) 19 (7) 0.21
D MCA Vm (%) 11 (7) 19 (6)
*y 12 (3) <0.01
D PCA Vm-MCA Vm (%) 12.5 (8.1) 0.1 (7.6)
*§ 6.8 (8.7) <0.01
D MAP (%) 1 (2) 4 (3)* 3 (2)* <0.01
D PCACVCi (%) 26 (9) 18 (8)* 17 (8)* <0.05
D MCACVCi (%) 13 (6) 17 (6)
y 10 (4) <0.05
D PCACVCi-MCACVCi (%) 12.9 (9.2) 1.0 (7.5)* 6.6 (9.4) <0.01
D PETCO2 (%) 3 [100–104] 2 [101–104] 2 [100–104] 0.51
D PCA Vm / PETCO2 (%) 23 (8) 19 (8) 18 (8) 0.26
D MCA Vm / PETCO2 (%) 11 (6) 19 (7)
*y 12 (5) <0.01
Note: Values are displayed as mean (SD) when normally distributed or median [interquartile range] when non-normally distributed. P values represent
ANOVA results. MCA: middle cerebral artery; PCA: posterior cerebral artery; Vm: mean blood flow velocity; MAP: mean arterial pressure; CVCi:
cerebrovascular conductance index; PETCO2: end-tidal partial pressure of CO2.
*P< 0.05 vs. HC; yP< 0.05 vs. HT; §P¼ 0.056 vs. HT.
Table 3. Cerebrovascular, haemodynamic and respiratory responses to a single sit-stand manoeuvre in healthy controls (HC),
patients with atrial fibrillation (AF) and hypertension (HT).
HC AF HT P value
n 24 30 29
Baseline (sitting)
MCA Vm (cm/s) 59 (17) 53 (14) 49 (10)* 0.03
MAP (mmHg) 100 [94–108] 98 [83–112]y 117 [108–128]* <0.01
MCACVCi (cm/s/mmHg) 0.54 [0.46–0.77] 0.51 [0.39–0.64]
y 0.42 [0.35–0.46]* <0.01
PETCO2 (mmHg) 37 [35–39] 38 [33–40] 38 [36–40] 0.39
Change from sitting to nadir during standing
D MCA Vm (%) 14 [18–9] 15 [17–8] 11 [15–6] 0.23
Time to nadir of MCA Vm (s) 23 [6–34] 27 [6–33] 25 [8–32] 0.90
D MAP (%) 20 (8) 19 (10) 16 (9) 0.15
Time to nadir of MAP (s) 9 [8–11] 8 [7–11] 10 [8–12] 0.16
D MCACVCi (%) 10 [14–8] 11 [16–3] 7 [13–5] 0.47
Time to nadir of CVCi (s) 27 [22–40] 25 [3–34] 30 [4–40] 0.74
D PETCO2 (%) 5 [10–3] 7 [9–5] 6 [9–2] 0.85
Note: Values are displayed as mean (SD) when normally distributed or median [interquartile range] when non-normally distributed. P values represent
ANOVA results. *P< 0.05 vs. HC; yP< 0.05 vs. HT.
MCA: middle cerebral artery; Vm: mean blood flow velocity; MAP: mean arterial pressure; CVCi: cerebrovascular conductance index; PETCO2: end-
tidal partial pressure of CO2.
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coherence was appreciably increased by performance of
the squat-stand manoeuvre in all groups.
Subgroup analysis of AF patients being tested during
an AF episode or not
Approximately 50% of AF patients were in AF when
studied, and so a subgroup analysis was undertaken
between these patients compared to those not in AF
when tested. Groups were not different in terms of
age, hip-to-waist ratio, SBP, PCA Vm, PETCO2,
whereas HR, BMI (tendency, P¼ 0.08), DBP (ten-
dency, P¼ 0.06) and MAP (tendency, P¼ 0.06) were
higher, and MCA Vm was lower in those AF patients
that were fibrillating when tested (Supplementary
Table 2). Neither neurovascular coupling
(Supplementary Table 3), nor the cardiovascular and
cerebrovascular responses to the sit-stand manoeuvre
were different in these sub-groups of AF patients
(Supplementary Table 4). Supplementary Table 5
Figure 2. Cerebral autoregulation determined using transfer function analysis during a repeated squat-stand manoeuvre at 0.10 Hz
in healthy controls (HC; blue), patients with atrial fibrillation (AF; red) and hypertension (HT; green). Panels a and b show original
records of arterial blood pressure (BP) and middle cerebral artery mean blood flow velocity (MCA Vm) at baseline (supine) and during
repeated squat-stands in one healthy participant. Panels c and d show transfer function normalised gain and phase determined during
the repeated squat-stand manoeuvre at 0.10 Hz in each study group with mean (SD). *P< 0.05 vs. HC; yP< 0.05 vs. HT.
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provides transfer function analysis derived coherence,
phase and gain at 0.1Hz, both at baseline and during a
repeated squat-stand manoeuvre. Interestingly, during
the squat-stand manoeuvre, absolute gain was lower
(0.64 [0.22] vs. 0.92 [0.37] cm/s/mmHg) and phase was
higher (0.63 [0.25] vs. 0.35 [0.17] radians) in AF patients
that were fibrillating when studied (P< 0.05).
Discussion
The aim of this study was to determine whether neuro-
vascular coupling and cerebral autoregulation are
impaired in AF. Our major novel findings are that:
(1) individuals with AF have a blunted neurovascular
coupling response to visual stimulation when compared
to age-matched healthy controls; (2) cerebral autoregu-
lation is diminished in AF patients as indicated from
the elevated normalised gain derived from transfer
function analysis, and (3) AF patients that were fibril-
lating when studied had a lower cerebral perfusion
(MCA Vm) than those AF patients not in AF when
tested, but cerebral autoregulatory performance was
not less effective.
Neurovascular coupling
A complex array of signalling cascades normally cou-
ples neuronal activation and metabolism to cerebral
blood flow with a high spatial and temporal fidelity.20
A diminished neurovascular coupling, indicative of
cerebrovascular dysfunction, has been demonstrated
in several clinical conditions (e.g., stroke, Alzheimer’s
disease),9,21 and while an association between impaired
neurovascular coupling and diminished cognitive func-
tion has been reported,33 human studies of causality are
awaited. In the present study, we observed that
increases in visual stimulation evoked a blunted
PCACVCi response in patients with AF compared to
healthy control participants, indicative of diminished
neurovascular coupling. This may be attributable to
visual stimulation causing a blunted neuronal activa-
tion in AF as sub-clinical neurodegeneration can
occur in some cases,34 or alternatively a disruption in
the coupling between neuronal activation and increases
in local blood flow.
A multitude of substances are believed to link neur-
onal and astrocytic activation to local vasodilatation,
including vasoactive ions (e.g. potassium, hydrogen),
metabolites (e.g. adenosine, lactate), neurotransmitters
(e.g. glutamate, dopamine) and factors derived from
the endothelium (e.g. NO).21,35 Endothelial damage/
dysfunction has been reported in AF, and may in
part be due to blood flow abnormalities associated
with an irregular heart rate, with resultant turbulent
flow both in the left atrium and systemically.36
Loss of shear stress, which occurs in conditions of tur-
bulent flow, decreases endothelial NO synthase expres-
sion as compared with laminar or pulsatile flow
conditions.37,38 Diminished NO signalling may contrib-
ute to the diminished neurovascular coupling we
report.35 However, in contrast to the abundance of stu-
dies employing isolated preparations and non-human
models, the mechanistic basis of neurovascular cou-
pling has been more sparsely studied in humans.21
Further studies are needed to better understand the
physiological mechanisms for the observed deficit in
the cerebral perfusion response of the occipital lobe
to visual stimulation in AF patients.
Patients with hypertension were observed to have a
lower PCACVCi response to visual stimulation in com-
parison with healthy control participants. This is in
general agreement with a previous report of a blunted
cerebral blood flow response in the parietal cortex
during a memory task in untreated hypertension
patients compared to normotensive controls.33
Interestingly, a poorer cerebral blood flow response
was associated with a worse cognitive performance.33
In mice, the systemic administration of angiotensin II
raises blood pressure and diminishes the cerebral blood
flow response to whisker stimulation (i.e. a blunted
neurovascular coupling response).39 Given that phenyl-
ephrine administration to induce a similar pressor
response to angiotensin II did not blunt the hyperaemic
response to whisker stimulation, hypertension per se
does not appear to explain the blunted neurovascular
coupling and perhaps points to an effect of angiotensin
II on a vascular regulation (e.g. vascular oxidative
stress, diminished NO bioavailability).39,40 In the pre-
sent study, PCACVCi responses to visual stimulation
were similar in patients with AF and hypertension.
This occurred despite the known right-shift in the cere-
bral autoregulation curve documented in hypertension,
which is reported to have a complex influence on the
neurovascular coupling response,41,42 and may relate to
the diminished vasoactive signalling mechanisms
described above. Of note, AF patients exhibited a
larger MCACVCi and MCA Vm response than patients
with hypertension. The MCA does not supply the
visual cortex and this ‘‘non-selective’’ response may
reflect the engagement of cognitive pathways that are
independent of visual cortex stimulation.43
Interestingly, when the ‘‘non-selective’’ MCACVCi and
MCA Vm responses to the neurovascular coupling test
were subtracted from the PCACVCi and PCA Vm
responses in a secondary analysis, AF patients dis-
played the poorest neurovascular coupling of all the
groups studied (i.e. the lowest percentage increase in
PCACVCi and PCA Vm). Diminished neurovascular
coupling, may over time, disrupts the neuronal micro-
environment and causes functional deficits in the brain.
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Cerebral autoregulation
An impaired cerebral autoregulation has been identified
in conditions including traumatic brain injury,44
Alzheimer’s disease,45 type 2 diabetes mellitus46 and
following mild ischaemic stroke.47 In accordance with
previous studies, we observed that MCA Vm (an index
of cerebral perfusion) was reduced in AF patients in the
supine position, and this has previously been postulated
to be both a cause12 and a consequence11 of an
impaired cerebral autoregulation. A number of com-
plex mechanisms are involved in the autoregulatory
process and include stretch-activated cation channels,48
autonomic influences49 metabolic influences (e.g.
CO2),
50 and NO,18,19 although the latter is still
debated.17 As described above, endothelial damage/
dysfunction and diminished endothelial NO bioavail-
ability have been identified in AF,13,14 along with auto-
nomic imbalance.51 Our study is the first to determine
whether cerebral autoregulation is impaired in AF and
this was assessed using two approaches. First, the
examination of the temporal pattern of the MCA Vm
and MAP responses to a simple sit–stand manoeuvre,
and second, the transfer function analysis of these same
signals during a repeated squat-to-stand manoeuvre.
Importantly, these manoeuvres have high ecological
validity as they commonly occur in normal everyday
life (e.g. rising from a chair or standing up after retriev-
ing something from the floor) and can be accompanied
by symptoms indicative of cerebral hypoperfusion (e.g.
light-headedness). Both manoeuvres evoke pronounced
changes in blood pressure, and in the case of the
repeated squat-to-stand manoeuvre, the large oscilla-
tions in blood pressure evoked are transmitted to cere-
bral perfusion (Figure 2), thus increasing the coherence
between these variables and optimizing the transfer
function analysis method and its reproducibility.27,28
In line with our hypothesis, cerebral autoregulation
was diminished in AF patients compared to either
healthy controls or patients with hypertension (i.e. nor-
malised gain was elevated). A higher gain is usually
indicative of poorer buffering of changes in MAP by
the cerebral vasculature, but it can also suggest a
decreased cerebral vascular resistance.29 PETCO2 was
similar between groups during sit–stand test and
slightly diminished in AF patients compared to those
with hypertension, during supine baseline coincident
with transfer function analysis. Of note, as hypercapnia
decreases autoregulation,50 these differing PETCO2
levels are unlikely to explain the group differences
observed in cerebral autoregulation. A sub-group ana-
lysis of AF patients that were fibrillating (paroxysmal
and persistent AF) versus those not in AF (paroxysmal
AF) when tested identified that the former group had a
reduced transfer function absolute gain and increased
phase. Phase is representative of the delay between the
input (MAP) and output (MCA Vm), and a lower phase
shift may indicate a more passive following of MCA Vm
to MAP, thus a reduced cerebral autoregulatory per-
formance.52,53 The lower absolute gain and increased
phase observed suggest a more effective cerebral auto-
regulation in the AF patients that were fibrillating when
studied. This puzzling observation may be directly
attributable to the fibrillation per se, but the contribu-
tion of a secondary related factor, such as the higher
MAP (tendency) and lower MCA Vm, cannot be
excluded. Indeed, normalised gain, which negates
group differences in MCA Vm, was not different
between AF sub-groups. Additional studies are
required to better understand the mechanisms, whereby
cerebral autoregulation may be altered in this popula-
tion. Interestingly, there were no between-group differ-
ences in the cerebral perfusion response to the single
sit–stand manoeuvre, suggesting that the more haemo-
dynamically strenuous manoeuvre (i.e. repeated squat-
to-stand) was required to reveal the AF-related alter-
ations in cerebral autoregulation.
Limitations
The reported changes in MCA Vm and PCA Vm derived
using transcranial Doppler ultrasound are only propor-
tional to cerebral blood flow if the cross-sectional area
of the insonated artery remains unchanged. Of note, the
transcranial Doppler technique is the only practical
way we could have quantified the cerebral perfusion
responses to posturally induced changes in blood pres-
sure and thus derive cerebral autoregulatory data. An
increase in AF burden from paroxysmal to persistent,
and the duration of AF and hypertension since diagno-
sis, might be expected to further worsen cerebrovascu-
lar function. However, this information for individual
patients was not obtained thus limiting further within
group analysis. Investigations of sub-clinical indices of
end-organ damage and cerebral scans for covert
infarcts were beyond the scope of the protocol and as
such were not performed.
Conclusions
Neurovascular coupling and cerebral autoregulation
are diminished in AF patients compared to age-
matched, healthy controls and patients with hyperten-
sion. Future studies should explore the molecular basis
for these observations, along with their clinical impli-
cations as they may be significant in terms of
AF-related cognitive decline and brain dysfunction.
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